Medpace Gains as Major U.S. Indexes Close Lower
Shares rose 1% as the S&P 500, Dow and Nasdaq declined; analysts expect earnings growth in Medpace’s October report.
Medpace shares closed 1% higher at $622.11 in the latest session, while the S&P 500 fell 0.17%. The Dow lost 0.26%, and the Nasdaq declined 0.09%.
Over the past month, the stock gained 3.7%. The Medical sector fell 0.67% and the S&P 500 lost 0.24% over the same period.
Medpace is scheduled to report earnings on October 21, 2026. Analysts expect quarterly earnings of $4.45 per share, up 15.28% from a year earlier, and revenue of $708.75 million, a 7.4% increase.
For the annual period, Zacks consensus estimates call for earnings of $17.54 per share and revenue of $2.84 billion. Those forecasts represent year-over-year growth of 14.79% and 12.38%, respectively; the consensus earnings estimate was unchanged over the past 30 days.
Zacks put Medpace’s forward P/E ratio at 35.12, compared with an industry average of 16.95. The ratio compares a company’s share price with its expected earnings.
This article was produced with the help of AI technology.
Source: Yahoo Finance
